-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MwyuYvlz3t7QD2fyaihlfhIGFKLWBkGD48YWowbvf5TvLaY27VptytGaMJxo169U
 7eJk26wgEb1kCROQWElVIQ==

<SEC-DOCUMENT>0001193805-08-001381.txt : 20080519
<SEC-HEADER>0001193805-08-001381.hdr.sgml : 20080519
<ACCEPTANCE-DATETIME>20080519163103
ACCESSION NUMBER:		0001193805-08-001381
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20080508
FILED AS OF DATE:		20080519
DATE AS OF CHANGE:		20080519

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYTOGEN CORP
		CENTRAL INDEX KEY:			0000725058
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				222322400
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0508

	BUSINESS ADDRESS:	
		STREET 1:		650 COLLEGE RD EAST STE 3100
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		6099878200

	MAIL ADDRESS:	
		STREET 1:		650 COLLEGE RD EAST STE 3100
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			EUSA Pharma Inc
		CENTRAL INDEX KEY:			0001359987

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14879
		FILM NUMBER:		08845623

	BUSINESS ADDRESS:	
		STREET 1:		2500 ONE LIBERTY PL
		STREET 2:		1650 MARKET ST.
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		215-851-8100

	MAIL ADDRESS:	
		STREET 1:		2500 ONE LIBERTY PL
		STREET 2:		1650 MARKET ST.
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>e603828_ex.xml
<DESCRIPTION>FORM 3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2008-05-08</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000725058</issuerCik>
        <issuerName>CYTOGEN CORP</issuerName>
        <issuerTradingSymbol>NASD:CYTO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001359987</rptOwnerCik>
            <rptOwnerName>EUSA Pharma Inc</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>HERITAGE GATEWAY CENTRE</rptOwnerStreet1>
            <rptOwnerStreet2>1980 S. EASTON ROAD, SUITE 250</rptOwnerStreet2>
            <rptOwnerCity>DOYLESTOWN</rptOwnerCity>
            <rptOwnerState>PA</rptOwnerState>
            <rptOwnerZipCode>18901</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>36093873</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">On May 8, 2008, the Reporting Person acquired all of the issued and outstanding shares of common stock, $0.01 par value, of
 the Issuer pursuant to an Agreement and Plan of Merger, dated March 10, 2008, among the Issuer, the Reporting Person, and
 EUSA Pharma (USA), Inc., a wholly-owned subsidiary of the Reporting Person. In the merger, EUSA Pharma (USA), Inc. merged
 with and into the Issuer. On May 8, 2008 a Form 25 was filed with the SEC to effect the delisting from The Nasdaq Global
 Market of the common stock of the Issuer. On May 9, 2008, a Form 15 was filed with the Securities and Exchange Commission
 (the &quot;SEC&quot;) to suspend the Issuer's duty to file reports required by Section 13 of the Securities Exchange Act and to
 terminate the registration of the common stock of the Issuer.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Zoe Evans</signatureName>
        <signatureDate>2008-05-08</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----